These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

764 related articles for article (PubMed ID: 14733418)

  • 1. Influence of sevelamer hydrochloride on serum concentration of whole (1-84) and N-terminally truncated (7-84) parathyroid hormone fragments in hemodialysis uremic patients.
    Chudek J; Piecha G; Kokot F; Wiecek A
    J Nephrol; 2003; 16(5):710-5. PubMed ID: 14733418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Meta-analysis of the effect of sevelamer on phosphorus, calcium, PTH, and serum lipids in dialysis patients.
    Burke SK; Dillon MA; Hemken DE; Rezabek MS; Balwit JM
    Adv Ren Replace Ther; 2003 Apr; 10(2):133-45. PubMed ID: 12879374
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is 2.5 mEq/L the optimal calcium concentration of dialysate in the use of sevelamer hydrochloride? A study of the dialysate calcium concentration recommended by K/DOQI guidelines.
    Izumi M; Shirai K; Ito K; Miyamoto T; Matsumoto A; Takenaka Y; Nakagawa K; Yamanashi T; Takamitsu Y; Nakanish T
    Ther Apher Dial; 2005 Feb; 9(1):24-31. PubMed ID: 15828902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and side-effect profile of sevelamer hydrochloride used in combination with conventional phosphate binders.
    Sturtevant JM; Hawley CM; Reiger K; Johnson DW; Campbell SB; Burke JR; Bofinger A; Isbel NM
    Nephrology (Carlton); 2004 Dec; 9(6):406-13. PubMed ID: 15663645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decrease in thoracic vertebral bone attenuation with calcium-based phosphate binders in hemodialysis.
    Raggi P; James G; Burke SK; Bommer J; Chasan-Taber S; Holzer H; Braun J; Chertow GM
    J Bone Miner Res; 2005 May; 20(5):764-72. PubMed ID: 15824849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sevelamer reduces calcium load and maintains a low calcium-phosphorus ion product in dialysis patients.
    Gallieni M; Cozzolino M; Carpani P; Zoni U; Brancaccio D
    J Nephrol; 2001; 14(3):176-83. PubMed ID: 11439741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of sevelamer on mineral and lipid abnormalities in hemodialysis patients.
    Hamida FB; Fatma LB; Barbouch S; Kaaroud H; Helal I; Hedri H; Abdallah TB; Maiz HB; Kheder A
    Saudi J Kidney Dis Transpl; 2008 Mar; 19(2):183-8. PubMed ID: 18310864
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes of bone markers during long-term intravenous calcitriol therapy in maintenance dialysis patients.
    Lee SH; Huang TS; Hsieh SJ
    Miner Electrolyte Metab; 1996; 22(4):219-23. PubMed ID: 8807625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Defining the role of sevelamer chloride as a therapeutic agent for management of phosphate in patient with hemodialysis].
    Hashimoto N; Miyata M; Sato N; Mochizuki T; Koike T
    Clin Calcium; 2005 Sep; 15 Suppl 1():30-4; discussion 34. PubMed ID: 16272626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Relationship between serum calcium level and PTH concentration proved with sevelamer hydrochloride].
    Ito M; Mochizuki T; Koike T; Hashimoto N; Fukazawa S; Akatsuka T; Niida Y; Tozawa S; Yasuda T; Sato M
    Clin Calcium; 2005 Sep; 15 Suppl 1():11-13; discussion 13-4. PubMed ID: 16279016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of sevelamer. Comparison with calcium carbonate in the treatment of hyperphosphatemia in hemodialysis patients.
    Shaheen FA; Akeel NM; Badawi LS; Souqiyyeh MZ
    Saudi Med J; 2004 Jun; 25(6):785-91. PubMed ID: 15195212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Front line of management of hyperphosphatemia in hemodialysis patients].
    Yumita S
    Clin Calcium; 2004 May; 14(5):771-7. PubMed ID: 15577041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Experience with sevelamer in peritoneal dialysis].
    Ortiz A; Ríos F; Melero R; Reyero A; Gazapo R; Casado S
    Nefrologia; 2003; 23(5):432-6. PubMed ID: 14658169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of sevelamer in the treatment of uncontrolled hyperphosphataemia of haemodialysis patients.
    Almirall J; Lopez T; Vallve M; Ruiz A; Llibre J; Betriu A
    Nephron Clin Pract; 2004; 97(1):c17-22. PubMed ID: 15153763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Length of interdialytic interval influences serum calcium and phosphorus concentrations.
    Sigrist MK; Devlin L; Taal MW; Fluck RJ; McIntyre CW
    Nephrol Dial Transplant; 2005 Aug; 20(8):1643-6. PubMed ID: 15870223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment with phosphate binder (sevelamer hydrochloride, calcium carbonate) based on PTH].
    Sato M; Fukazawa S; Yasuda T; Akatsuka T; Tozawa S; Niida Y; Hashimoto N; Mochizuki T; Koike T
    Clin Calcium; 2005 Sep; 15 Suppl 1():23-8; discussion 28-9. PubMed ID: 16272625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sevelamer worsens metabolic acidosis in hemodialysis patients.
    De Santo NG; Frangiosa A; Anastasio P; Marino A; Correale G; Perna A; Di Stazio E; Stellato D; Santoro D; Di Meglio E; Iacono G; Ciacci C; Savica V; Cirillo M
    J Nephrol; 2006; 19 Suppl 9():S108-14. PubMed ID: 16736432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of sevelamer and calcium-based phosphate binders on uric acid concentrations in patients undergoing hemodialysis: a randomized clinical trial.
    Garg JP; Chasan-Taber S; Blair A; Plone M; Bommer J; Raggi P; Chertow GM
    Arthritis Rheum; 2005 Jan; 52(1):290-5. PubMed ID: 15641045
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of sevelamer on dyslipidemia and chronic inflammation in maintenance hemodialysis patients.
    Yamada K; Fujimoto S; Tokura T; Fukudome K; Ochiai H; Komatsu H; Sato Y; Hara S; Eto T
    Ren Fail; 2005; 27(4):361-5. PubMed ID: 16060120
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.